The Visitor Training Program (VTP) is intended to help build hematology capacity in developing countries by providing funding for hematologists or hematology-related health care professionals in the developing world to receive specialized training for up to 12 weeks.
Co-formulated vibostolimab and pembrolizumab plus chemotherapy failed to improve OS in the first line vs atezolizumab plus chemotherapy in ES-SCLC.
An abstract is unavailable.
Matthew Cortese, MD, MPH, details 2024/2025 updates to the NCCN guidelines for CLL/SLL and treatments to look forward to in the future.
The FDA has granted orphan drug designation to LBL-034 for the treatment of patients with multiple myeloma.
John Strickler, MD, Duke Cancer Institute, Durham, NC, gives an overview of the NICHE-2 trial (NCT03026140), which assessed immunotherapy for non-metastatic MSI-high colon cancer. Traditionally…
Consultant Clinical Oncologist NHS advocate and campaigner Politically centre left Wealth inequality creates health inequality
The Visitor Training Program (VTP) is intended to help build hematology capacity in developing countries by providing funding for hematologists or hematology-related health care professionals…
At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.
Shaji Kumar, MD, details key updates/revisions made to the multiple myeloma NCCN guidelines in 2024 and the first version of the 2025 guidelines.
Promoting development of new drug and biological products to treat patients with rare cancers
